AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

BISMARCK, N.D. — (AP) — Much of the Upper Midwest on Saturday was dealing with swaths of unhealthy air because of drifting ...

According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion ...

The Big Beautiful Bill threatens our most vulnerable residents and endangers Baltimore’s recovery. Our city’s renaissance depends on accessible health care, and Baltimore will fight for legislation ...

After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Research shows that long-term exposure to wildfire smoke is linked to lung diseases, heart disease and other conditions. Since these illnesses take decades to develop, scientists think that the health ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...